{
    "2020-10-14": [
        [
            {
                "time": "",
                "original_text": "「少年得到」获近2亿元B轮融资；「摄星智能」完成数千万A轮融资；以及今天值得关注的早期项目",
                "features": {
                    "keywords": [
                        "融资",
                        "少年得到",
                        "摄星智能"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "教育",
                        "人工智能"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "市盈率上百倍、股价翻倍高瓴仍要买！CDMO行业有何魔力？",
                "features": {
                    "keywords": [
                        "市盈率",
                        "高瓴",
                        "CDMO",
                        "股价翻倍"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "多款新冠疗法及疫苗试验暂停 \"解药\"研发步履艰难",
                "features": {
                    "keywords": [
                        "新冠",
                        "疫苗",
                        "试验暂停",
                        "研发困难"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业2020三季度业绩前瞻：板块分化明显 医疗服务等板块有序复苏",
                "features": {
                    "keywords": [
                        "医药生物",
                        "业绩前瞻",
                        "板块分化",
                        "医疗服务",
                        "复苏"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "高瓴独享凯莱英23亿定增“梦破”！仍豪掷10亿不改初衷",
                "features": {
                    "keywords": [
                        "高瓴",
                        "凯莱英",
                        "定增",
                        "梦破",
                        "投资"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医药大健康赛道吸金能力仍强，头部机构不断加仓",
                "features": {
                    "keywords": [
                        "医药",
                        "大健康",
                        "吸金能力",
                        "头部机构",
                        "加仓"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "凯莱英定增一波三折终成行 发行价翻倍高瓴坚定布局A股医药版图",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "定增",
                        "发行价翻倍",
                        "高瓴",
                        "医药"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}